Investment Rating - The industry investment rating is maintained at "Overweight" [5] Core Insights - The approval of four innovative drugs by the National Medical Products Administration (NMPA) on December 15, 2025, marks a significant milestone for the Chinese pharmaceutical industry, indicating a concentrated effort to enhance the efficiency of drug approval processes and support for urgently needed clinical medications [5][7] - The approved drugs demonstrate significant clinical differentiation and market potential, with clear commercial value, such as the innovative anti-influenza drug from Health元, which offers a single-dose administration, addressing existing treatment challenges [7] - The approval process highlights a "stronger gets stronger" trend, where leading companies are recognized not only for individual products but also for their underlying research and commercialization capabilities, reinforcing their market positions [7] Summary by Sections Recent Industry Performance - The industry has shown relative returns of -3.06% over the past month, -9.84% over the past three months, and -7.91% over the past year, while absolute returns were 0.49% for the last month, -7.88% for the last three months, and 9.5% for the last year [3] Investment Highlights - The approval of four innovative drugs signifies a new phase of high-quality development in the pharmaceutical industry, with a more streamlined process from research and evaluation to market entry [7] - The drugs approved have demonstrated strong clinical efficacy, with the TRK inhibitor showing an objective response rate of 89.1%, fulfilling urgent needs in precision oncology [7] - The report suggests focusing on companies that will directly benefit from these approvals, such as Health元, 诺诚健华, and 恒瑞医药, as they represent key players in the market [7]

Investment Rating - The industry investment rating is "Overweight" (maintained) [7] Core Insights - The report highlights the significant breakthrough of Fuhong Hanlin's PD-1 inhibitor, H drug, which has received acceptance for registration for perioperative treatment of resectable gastric cancer, marking a key advancement in tumor immunotherapy [7] - The global tumor immunotherapy market is projected to grow at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2031, indicating a substantial market opportunity as the treatment landscape expands from late-stage to early-stage therapies [7] - The report emphasizes the potential for A-share companies to benefit from this innovation, particularly those involved in tumor immunotherapy and related services [7] Summary by Sections Industry Performance - The industry has shown relative returns of -3.06% over the past month, -9.84% over the past three months, and -7.91% over the past year compared to the CSI 300 index [3] Recent Developments - The report discusses various recent developments in the pharmaceutical and biotechnology sector, including supportive policies in Sichuan and significant collaborations in the industry [4] Investment Recommendations - The report suggests focusing on "frontier breakthrough leaders" and "core assets in tumor innovation," recommending attention to companies such as Heng Rui Medicine, WuXi AppTec, and Kelun Pharmaceutical [7]

Investment Rating - The industry investment rating is maintained at "Overweight" [5] Core Insights - The management change at WuXi AppTec is seen as a strategic move to leverage the expertise of both commercial and technical leaders to navigate the evolving payment landscape for CAR-T therapies. The new CEO, Tian Feng, brings over 20 years of experience in oncology commercialization, while the new chairman, Dr. Liu Cheng, is a leading scientist in the CAR-T field [5][7] - The establishment of the first national commercial health insurance innovation drug directory marks a significant shift in China's multi-tiered payment system, providing new payment channels for high-cost therapies like CAR-T. This policy change indicates a transition in market focus from "technical validation" to "payment capability and market access" [7] - The management aims to capitalize on this policy window by enhancing collaborations with insurance companies and optimizing costs, such as reducing core material costs by over 90% through self-developed lentiviral vectors. This strategic adjustment signals a broader industry shift from research-driven to a dual focus on research and commercialization [7] Summary by Sections Recent Industry Performance - The industry has shown relative returns of -3.06% over the past month, -9.84% over the past three months, and -7.91% over the past year compared to the CSI 300 index. Absolute returns were 0.49% for the last month, -7.88% for the last three months, and 9.5% for the last year [3] Management Changes - WuXi AppTec announced significant changes in its core management team, appointing Tian Feng as the new CEO and Dr. Liu Cheng as the chairman. This change is crucial as the company seeks to enhance its market performance amid evolving industry challenges [5][7] Investment Recommendations - The report suggests focusing on companies within the A-share market that have a strong position in the cell therapy industry, such as WuXi AppTec, Fosun Pharma, and others, due to the anticipated opportunities arising from the breakthrough in CAR-T therapy payment bottlenecks [7]

执业证书编号：S1410524040001 江省资本市场跟踪双周报— （2025.11.23-2025.12.6) – 2025.12.08 2. 江海证券-黑龙江省资本市场跟踪-黑龙 江省资本市场跟踪双周报— （2025.11.9-2025.11.22）– 2025.11.24 3. 江海证券-黑龙江省资本市场跟踪-黑龙 江省资本市场跟踪双周报— （2025.10.26-2025.11.8） – 2025.11.10 4. 江海证券-黑龙江省资本市场跟踪-黑龙 江省资本市场跟踪双周报— （2025.10.12-2025.10.25） – 2025.10.29 5. 江海证券-黑龙江省资本市场跟踪-黑龙 江省资本市场跟踪双周报— （2025.9.21-2025.10.11） – 2025.10.14 黑龙江省资本市场跟踪双周报 — — （2025.12.7-2025.12.20） 证券研究报告·黑龙江省资本市场跟踪报告 2025 年 12 月 22 日 江海证券研究发展部 机械军工行业研究组 分析师：张诗瑶 投资要点： 江海证券有限公司及其关联机构在法律许可的情况下可能与本报告所分析的企业存在业务关系，并且继 ...

证券研究报告·黑龙江省资本市场跟踪报告 2025 年 12 月 22 日 江海证券研究发展部 执业证书编号：S1410524040001 江省资本市场跟踪双周报— （2025.11.23-2025.12.6) – 2025.12.08 2. 江海证券-黑龙江省资本市场跟踪-黑龙 江省资本市场跟踪双周报— （2025.11.9-2025.11.22）– 2025.11.24 3. 江海证券-黑龙江省资本市场跟踪-黑龙 江省资本市场跟踪双周报— （2025.10.26-2025.11.8） – 2025.11.10 4. 江海证券-黑龙江省资本市场跟踪-黑龙 江省资本市场跟踪双周报— （2025.10.12-2025.10.25） – 2025.10.29 5. 江海证券-黑龙江省资本市场跟踪-黑龙 江省资本市场跟踪双周报— （2025.9.21-2025.10.11） – 2025.10.14 黑龙江省资本市场跟踪报告 机械军工行业研究组 黑龙江省资本市场跟踪双周报 — — 分析师：张诗瑶 （2025.12.7-2025.12.20） 投资要点： | 图 | 1 、12 | 月以来大类资产表现情况 3 | | ...

Investment Rating - The industry investment rating is maintained at "Overweight" [5] Core Insights - The Sichuan provincial government has issued a comprehensive policy to support the high-quality development of the biopharmaceutical and medical device industries, addressing long-standing issues such as lengthy R&D cycles and market access challenges [5][7] - The policy includes 21 specific measures aimed at creating a full-chain innovation ecosystem, providing financial support for approved innovative drugs and medical devices, and significantly reducing approval times for product launches [5][7] - The policy is expected to benefit local leading enterprises with strong R&D capabilities, such as Baillie Tianheng and Kelun Pharmaceutical, by offering them financial and regulatory advantages [7] Summary by Sections Recent Industry Performance - The industry has shown relative returns of -1.87% over the past month, -9.27% over the past three months, and -6.57% over the past year compared to the CSI 300 index [3] Investment Highlights - The policy provides up to 15 million yuan in provincial financial support for Class 1 innovative drugs and up to 2 million yuan for innovative medical devices, reducing R&D risks and financial pressures for companies [7] - Approval times for drug applications have been significantly reduced, with technical review times for supplementary drug applications cut from 200 working days to 60, and for Class II medical devices to 35 working days [7] - The policy also facilitates market access by requiring the dynamic compilation of new and innovative drug and device directories, ensuring that hospitals can procure these products promptly [7]

- The report primarily focuses on tracking and analyzing the performance of broad-based indices in the A-share market, including their daily investment dynamics, moving averages, turnover rates, risk premiums, PE-TTM, dividend yields, and net asset break rates[1][2][4] - The turnover rate of the indices is calculated as the sum of the free-float market capitalization of constituent stocks multiplied by their turnover rates, divided by the total free-float market capitalization of the constituent stocks[17] - The risk premium is measured relative to the yield of 10-year government bonds, serving as a reference for risk-free rates, to evaluate the relative investment value and deviation of the indices[27][29] - The PE-TTM (Price-to-Earnings Trailing Twelve Months) is used as a valuation reference to assess the investment value of the indices at the current point in time[37][41] - Dividend yield is tracked to reflect the cash dividend return rate, which is particularly significant during market downturns as high dividend yields often act as a safe haven[46][51] - The net asset break rate is defined as the proportion of stocks with a price-to-book ratio below 1, indicating undervaluation in the market[52][55]

证券研究报告·金融工程报告 2025 年 12 月 19 日 江海证券研究发展部 金融工程定期报告 金融工程研究组 A 股市场快照：宽基指数每日投资动态 2025.12.19 ◆市场表现：2025 年 12 月 18 日, 各宽基指数（表 1）涨跌各现，其中上证 50（0.23%） 投资要点： 分析师：梁俊炜 执业证书编号：S1410524090001 A 股市场快照：宽基指数每日投资动 和中证 2000（0.07%）上涨，而创业板指（-2.17%）和沪深 300（-0.59%）跌幅最大。 当年涨跌情况，创业板指（45.08%）涨幅最大，其次是中证 2000（30.58%）和中 证 500（24.02%），中证 1000（22.07%）和中证全指（20.69%）涨幅缩小，而上证 50（11.69%）涨幅最小。 ◆均线比较：除了上证 50 和沪深 300，其余跟踪指数跌破 5 日均线。除上证 50， 其余跟踪指数跌破 10 均线及 60 日均线支撑位。 ◆资金占比与换手：2025 年 12 月 18 日, 中证 2000（25.25%）交易金额占比最高， 相关研究报告 态 2025.12.18 A 股市场快照： ...

Content: --------- <doc id='1'>证券研究报告·金融工程报告 2025 年 12 月 18 日 江海证券研究发展部 金融工程定期报告 金融工程研究组 A 股市场快照：宽基指数每日投资动态 2025.12.18 ◆市场表现：2025 年 12 月 17 日, 各宽基指数（表 1）全部上涨，其中创业板指（3.39%） 投资要点：</doc> <doc id='2'>分析师：梁俊炜 执业证书编号：S1410524090001 A 股市场快照：宽基指数每日投资动 和中证 500（1.95%）涨幅最大。当年涨跌情况，创业板指（48.3%）涨幅最大，其 次是中证 2000（30.48%）和中证 500（24.66%），中证 1000（22.34%）和中证全指 （21.17%）涨幅扩大，而上证 50（11.43%）涨幅最小。 ◆均线比较：除了中证 1000 和中证 2000，其余跟踪指数已突破 5 日及 20 日均线。 创业板指率先突破 60 日均线。各跟踪指数单日修复程度较大。 ◆资金占比与换手：2025 年 12 月 17 日, 沪深 300（25.34%）交易金额占比最高， 相关研究报告</doc> <doc id='3'>态 2025.12.17 A 股市场快照：宽基指数每日投资动 态 2025.12.16 A 股市场快照：宽基指数每日投资动 态 2025.12.15 其次是中证 2000（23.94%）和中证 1000（20.51%）。各宽基指数当前换手率分别 为中证 2000（3.88），创业板指（2.41），中证 1000（2.24），中证全指（1.63）， 中证 500（1.56），沪深 300（0.54）和上证 50（0.23）。 ◆日收益率分布：创业板指的峰度负偏离最大，中证 1000 的峰度负偏离最小。上 证 50 和创业板指的负偏态最大，中证 1000 和中证 2000 的负偏态最小。 ◆风险溢价：2025 年 12 月 17 日, 创业板指（97.14%）和中证 500（96.59%）风险 溢价近 5 年分位值较高，中证 1000（88.41%）和中证 2000（69.05%）较低。</doc> <doc id='4'>◆PE-TTM：中证 500（95.04%）和中证 1000（93.47%）分位值较高，而中证 2000 （79.17%）和创业板指（57.69%）分位值较低。 ◆股债性价比：没有指数高于其 80%分位，中证 500 低于其 20%分位。 ◆股息率：创业板指（63.22%）和中证 1000（51.65%）所处近 5 年历史分位值较 高，而中证 2000（31.32%）和中证 500（24.55%）较低。 ◆破净率：当前，各指数破净率为上证 50（22.0%），沪深 300（16.33%），中证 500（11.2%），中证 1000（8.3%），中证 2000（3.8%），创业板指（nan%）和中 证全指（6.51%）。 ◆风险提示：本报告可能存在数据缺失、数据错误、数据不及时、模型处理错误 等风险。本报告仅从金融工程角度，对重要指数的市场数据进行跟踪、统计、分 析，不构成对市场指数、行业或个股进行预测或推荐。</doc> <doc id='6'>| 市场衣乳… | | --- | | 1.1 指数表现 … | | 1.2 指数与均线的比较 | | 1.3 资全占比与换手率 … | | 2 日收益分布 | | 2.1 收益区间分布对比 | | 22 分布形态变化对比 | | 3 风险溢价 … | | 3.1 各宽基指数的风险溢价 | | 32 风险溢价历史分布 | | 4 PE-TTM. | | 4.1 各宽某指数 PE-TTM 和分位值 | | 4.2 PE-TTM 历史对比… | | 4.3 股债性价比历史对比… | | 5 吸血率… | | 5.1 近一年各宽某指数股息率变化情况, | | 5.2 股息率历史对比… | | 6 玻璃率 | | 7 风险提示 . |</doc> <doc id='8'>| 表 1、各宽基指数表现情况 | | --- | | 表 2、各宽基指数与均线、近250交易日高位和低位的比较 … | | 表 3 、各宽基指数分布形态变化 … | | 表 4、各宽基指数和十年期国债即期收益率的风险溢价 | | 表 5、各宽基指数 PE-TTM 分位值和历史值 | | 表 6、各宽基指数当前股息率和历史情况 | | 图 1、各宽基指数交易全额占比和换手率 | | 图 2、各宽基指数每日收益率分布情况 | | 图 3、各宽基指数相对十年国债即期收益率的风险溢价 | | 图 4、各宽基指数相对沪深 300 的风险溢价的近 5年分布 . | | 图 5 、各宽基指数 PE-TTM 及其分位值 | | 图 6、各宽基指数的股债性价比… | | 图 7、各宽基指数股息率 | | 图 8、各宽基指数破净个股数和占比………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 10 |</doc> <doc id='10'>1 市场表现 本报告将从指数涨跌幅、连阴连阳、上涨下跌分布等维度对各宽基指数进 行评价和跟踪。 1.1 指数表现 </doc> <doc id='11'>2025 年 12 月 17 日, 各宽基指数（表 1）全部上涨，其中创业板指（3.39%） 和中证 500（1.95%）涨幅最大。当周涨跌情况，各跟踪指数全部下跌，其中 中证 2000（-1.22%）和中证 1000（-1.12%）跌幅最大。当月涨跌情况，各跟踪 指数涨跌各现，其中创业板指（4.04%）和中证 500（1.51%）涨幅最大，而中 证 2000（-0.89%）和中证 1000（-0.62%）下跌。当季涨跌情况，各跟踪指数除 了上证 50（0.09%）外全部下跌，其中中证 1000（-3.78%）和中证 500（-3.7%） 跌幅最大。当年涨跌情况，创业板指（48.3%）涨幅最大，其次是中证 2000（30.48%） 和中证 500（24.66%），中证 1000（22.34%）和中证全指（21.17%）涨幅扩大， 而上证 50（11.43%）涨幅最小。 表 1、各宽基指数表现情况 指数名称 指数代码 当日涨幅% 当周涨幅% 当月涨幅% 当季涨幅% 当年涨幅% 日K </doc> <doc id='12'>| 指数名称 | 指数代码 | 当日涨幅% | 当周涨幅% | 当月涨幅% | 当季涨幅% | 当年涨幅% | 日K 连阴连阳 | 周K 连阴连阳 | 月K 连阴连阳 | 季K 连阴连阳 | 年K 连阴连阳 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 上证50 | 000016.SH | 1.25 | -0.10 | 0.74 | 0.09 | 11.43 | | | |

- The report primarily focuses on tracking and analyzing the performance of broad-based indices in the A-share market, including their daily, weekly, monthly, and yearly returns, as well as their relative positions to moving averages and historical highs and lows[1][10][14] - The analysis includes metrics such as trading turnover rates, with indices like CSI 2000 (3.93) and CSI 1000 (2.34) showing the highest turnover rates among the broad-based indices on December 16, 2025[17] - The report evaluates the distribution of daily returns for indices, highlighting characteristics such as kurtosis and skewness. For instance, the ChiNext Index exhibits the largest negative kurtosis deviation, while CSI 1000 shows the smallest negative kurtosis deviation. Similarly, the ChiNext Index has the largest negative skewness, and CSI 1000 has the smallest[23][25] - Risk premium analysis is conducted using the 10-year government bond yield as a risk-free rate benchmark. Indices like SSE 50 (12.22%) and CSI 2000 (10.56%) have relatively high 5-year percentile values, while ChiNext Index (8.25%) and CSI 500 (8.17%) are lower[27][31] - The report also examines valuation metrics such as PE-TTM. CSI 500 (93.88%) and CSI 1000 (93.14%) have the highest 5-year percentile values, while CSI 2000 (78.51%) and ChiNext Index (55.12%) are relatively lower[39][43] - Dividend yield analysis reveals that ChiNext Index (67.44%) and CSI 1000 (55.04%) are at higher 5-year historical percentiles, whereas SSE 50 (32.23%) and CSI 500 (28.1%) are at lower percentiles[51][53] - The report tracks the percentage of stocks trading below their book value (PB ratio < 1). As of the report date, the PB ratio percentages are as follows: SSE 50 (24.0%), CSI 300 (16.67%), CSI 500 (11.2%), CSI 1000 (8.3%), CSI 2000 (3.95%), and CSI All Share (6.61%)[57]